CCL22 and myeloid sarcoma: Treatment with natalizumab, a blocking antibody against the adhesion molecule integrin α4 and thereby a putative inhibitor of leukocyte transmigration to the CNS [77,78], was found to be associated with reduced CSF levels of CCL22, while CCL17 was below the detection threshold in MS patients before and after natalizumab treatment.